Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ataxin-7-like protein 1 (ATXN7L1)
- Target
- ATXN7L1
- Molecular classification
- Other (Homolog of transcriptional regulator/complex component; not a receptor, enzyme, ion channel, or transporter)
01
Overview
Ataxin-7-like protein 1 (ATXN7L1) is a protein coding gene and a paralog of ATXN7, which is a core component of the SAGA (Spt-Ada-Gcn5 acetyltransferase) chromatin remodeling complex[1][3]. ATXN7L1 shares significant amino acid homology with ATXN7 and is thought to have overlapping or compensatory functions, particularly in complex formation and chromatin regulation, although its precise molecular role is not well defined[1]. ATXN7L1, along with its paralogs, may substitute for ATXN7 or ATXN7L2 in specific stages of development or differentiation and has been implicated as a possible modulator of neurodegeneration through compensation mechanisms in models of spinocerebellar ataxia[1]. There is no current evidence that ATXN7L1 is a direct therapeutic target, and no drugs are known to interact with it[3].
- Other names
- Ataxin-7-like protein 1ATXN7L1Ataxin-7-like protein 4ATXN7L4KIAA1218MGC33190
02
Mechanism of action
Not applicable; no known drugs
03
Biological functions
Possible role in transcriptional regulationMay function as a component of chromatin modifying complexesPotential functional redundancy or compensation with ataxin-7, especially in the Spt-Ada-Gcn5 acetyltransferase (SAGA) complex’s deubiquitinase module[1]Possibly involved in development and cellular differentiation[1]
04
Disease associations
Neurodegenerative disease (implicated in the context of spinocerebellar ataxia 7 through paralogy and functional compensation, but direct evidence of causality is lacking)[1]Other (evidence of gene involvement in cellular proliferation and early cerebellar dysfunction in isolated cases)[1]
05
Safety considerations
None reported; functional deficiency in mouse models causes developmental defects and perinatal lethality, but there are no known therapeutic interventions targeting ATXN7L1[1]
06
Interacting drugs
None reported
07
Biomarkers
None reported
Beyond the preview
Go deeper on Ataxin-7-like protein 1 (ATXN7L1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ataxin-7-like protein 1 (ATXN7L1).